Antares Pharma (ATRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2021 | 12-2020 | 12-2019 | 12-2018 | 12-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 46,289 | 56,201 | -2,027 | -6,515 | -16,743 |
| Depreciation Amortization | 3,901 | 2,627 | 2,557 | 2,724 | 2,104 |
| Income taxes - deferred | 13,939 | -47,203 | -371 | N/A | N/A |
| Accounts receivable | -14,476 | -7,128 | -16,095 | -7,099 | -2,798 |
| Accounts payable and accrued liabilities | 2,189 | 2,594 | 926 | 5,164 | -1,522 |
| Other Working Capital | 1,595 | 690 | -17,986 | -6,811 | -11,628 |
| Other Operating Activity | -16,818 | 13,539 | 22,381 | -4,785 | 7,493 |
| Operating Cash Flow | $36,619 | $21,320 | $-10,615 | $-17,322 | $-23,094 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | 22,500 | N/A | 5,000 | 5,000 |
| PPE Investments | 11,208 | -9,333 | 2,650 | 6,646 | 734 |
| Purchase Of Investment | -1,245 | 0 | -22,645 | N/A | -9,964 |
| Purchase Sale Intangibles | -13,815 | -5,000 | N/A | -40 | -101 |
| Other Investing Activity | -13,815 | -5,000 | 0 | -40 | -101 |
| Investing Cash Flow | $-3,852 | $8,167 | $-19,995 | $11,606 | $-4,331 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 20,000 | 0 | 15,000 | N/A | 25,000 |
| Debt Repayment | -42,055 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 5,182 | 1,814 | 12,186 | 7,588 | 1,816 |
| Other Financing Activity | -3,117 | -1,367 | -1,267 | -543 | -543 |
| Financing Cash Flow | $-19,990 | $447 | $25,919 | $7,045 | $26,273 |
| Exchange Rate Effect | -1 | 2 | 0 | 1 | -1 |
| Beginning Cash Position | 53,137 | 23,201 | 27,892 | 26,562 | 27,715 |
| End Cash Position | 65,913 | 53,137 | 23,201 | 27,892 | 26,562 |
| Net Cash Flow | $12,776 | $29,936 | $-4,691 | $1,330 | $-1,153 |
| Free Cash Flow | |||||
| Operating Cash Flow | 36,619 | 21,320 | -10,615 | -17,322 | -23,094 |
| Capital Expenditure | -6,617 | -9,615 | -2,350 | -854 | -1,167 |
| Free Cash Flow | 30,002 | 11,705 | -12,965 | -18,176 | -24,261 |